BEIJING
InnoCare Pharmaceuticals (HKEX: 09969), a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for the treatment of cancer and autoimmune diseases, announced today that the company will present at the upcoming Morgan Stanley 2020 Virtual Asia Pacific Conference and ZGC Forum.
InnoCare CFO, Mr. Shaojing Tong, will join the China Biotech Panel of the Morgan Stanley conference to discuss and share the insights of China’s booming biotech industry on Thursday, September 24, 2020 China time.
Meanwhile, InnoCare will exhibit innovative medicine at the ZGC forum from September 17-20 in Beijing. Dr. Renbin Zhao, Executive Director of Biology and Clinical Development Strategy of InnoCare will present on the latest development of BTK inhibitor Orelabrutinib on the afternoon of Thursday, September 17, 2020, China time.
Founded in 2007, the ZGC forum has been held for years with the mission to promote communication, exchange, and cooperation in the field of science and technology worldwide.
About InnoCare Pharma
InnoCare Pharmaceuticals is a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune disease with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005364/en/
CONTACT
Media
Chunhua Lu
86-10-66609879
chunhua.lu@innocarepharma.com
Investor Relations
86-10-66609999
ir@innocarepharma.com
